Latest Asx News

IVE Group Limited has scheduled its half-year financial results release for February 24, 2025, alongside a notable governance change with Paul Selig moving from Executive to Non-Executive Director.

Mastermyne Group Limited reported a 14% rise in EBITDA to $4.1 million for FY25 Q2, even as revenue fell 10% due to operational disruptions at Anglo American’s Grosvenor mine. The company secured key contract extensions and maintained a strong cash position, positioning itself for growth amid sector uncertainties.

Patriot Lithium Limited has made significant strides in acquiring and exploring copper projects in Zambia while navigating complex negotiations for its key Gorman Lithium Project in Canada.

Core Energy Minerals Ltd has fortified its uranium exploration ambitions with a $3.7 million capital raise and strategic acquisitions in South Australia, setting the stage for a busy 2025 exploration calendar.

Pacific Current Group reports a 6.1% increase in total Funds Under Management to A$30 billion as of December 31, 2024, despite a decline in USD-denominated assets and exits from two boutique managers.

Peninsula Energy has delayed commissioning of its Lance Uranium Project’s Central Processing Plant to mid-2025, prompting a likely downgrade in annual production guidance amid ongoing operational challenges.

Pancontinental Energy reports encouraging technical progress on its PEL 87 project with improved reservoir confidence and ongoing drilling success in Namibia’s Orange Basin, underpinning a solid cash position.

Careteq Limited reports solid progress in integrating its Embedded Health Solutions with HMR Referrals, alongside a 14% revenue increase and improved cash flow in Q2 FY25.

Prophecy International has inked a three-year global reseller agreement with US SIEM leader Securonix, aiming to generate over $1 million in new annual recurring revenue within the first year.

Osteopore Limited reports a robust 27% year-over-year revenue increase despite operational headwinds, underpinned by new collaborations in stem cell therapies and expanded market access in Brazil and Singapore.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its clinical trial for Autosomal Dominant Optic Atrophy, marking a pivotal step in developing a treatment for this currently untreatable blinding disease.

Mesoblast has secured FDA approval for Ryoncil®, the first mesenchymal stromal cell therapy for steroid-refractory acute graft versus host disease in children, while raising A$260 million to accelerate clinical trials and commercial rollout.